 |
|
Treating Intraocular Inflammatory Disease in the 21st Century
Arch Ophthalmol. 2005;123:1000-1001.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Intraocular inflammatory disease, or uveitis, is a serious problem for the practitioner. A recent study1 puts the prevalence of this disorder at 115.3 per 100000 people, a number considerably higher than had been reported in the past. This translates into 322 000 people with this disease in the United States. More than 50 years ago, the treatment for uveitis underwent a tremendous paradigm shift with the introduction of corticosteroids into the ophthalmic therapeutic armamentarium. Although corticosteroids are initially effective in many patients, the adverse effects associated with their continued administration make them unacceptable as a long-term systemic therapy. The recent use of intraocularly placed steroids is still being evaluated, with major questions remaining as to the local adverse effects, what to do when the need to treat both eyes arises, and the required sustained long-term therapy that is needed in many patients.
Many of these uveitic disorders additionally show nonocular symptoms. . . . [Full Text of this Article]
AUTHOR INFORMATION
Robert Nussenblatt, MD
RELATED ARTICLE
A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes
Eric B. Suhler, Justine R. Smith, Michael S. Wertheim, Andreas K. Lauer, Daryl E. Kurz, Terri D. Pickard, and James T. Rosenbaum
Arch Ophthalmol. 2005;123(7):903-912.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Pilot Study on Ocular Safety of Intravitreal Infliximab in a Rabbit Model
Giansanti et al.
IOVS 2008;49:1151-1156.
ABSTRACT
| FULL TEXT
Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations
Sfikakis et al.
Rheumatology (Oxford) 2007;46:736-741.
FULL TEXT
|
